A meeting was held last week between the president of the Greek government’s Negotiation Committee, Nadia Gogozotou, and representatives of SFEE, the Hellenic Association of Pharmaceutical Companies.
During the discussion, there was a common understanding that thanks to the intense efforts of the Committee, many negotiations have been concluded, with the creation of closed and non-closed budgets, both for new products and for products already on the market, the trade group noted. This results in the faster reimbursement of the new products but also in the improvement of the National Organization for Healthcare’s (EOPYY) finances thanks to the additional discounts ensured and the significant improvement in cash flows, while at the same time, the State, at least for the time being, seems, thanks to the Negotiation Committee, to achieve the clawback reduction goal compared to 2020.
It became clear from the side of the SFEE that the continuous pressure due to high mandatory refunds has led to the delay of the introduction of new drugs in our country by 35%, as shown by an EFPIA study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze